News | Pharmaceuticals | May 26, 2017

Statins Associated With Improved Heart Structure and Function

Cardiac MRI scans reveal benefits occurred above and beyond the cholesterol lowering effect of statins

Statins Associated With Improved Heart Structure and Function

May 26, 2017 — Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May 25-27 in Prague. The research team reported the benefits were above and beyond the cholesterol lowering effect of statins.

“Statins are primarily used to lower cholesterol,” said lead author Nay Aung, M.D., a cardiologist and Wellcome Trust research fellow, William Harvey Research Institute, Queen Mary University of London, U.K. “They are highly effective in preventing cardiovascular events in patients who have had a heart attack or are at risk of heart disease.”

He continued: “Statins have other beneficial, non-cholesterol lowering effects. They can improve the function of the blood vessels, reduce inflammation and stabilize fatty plaques in the blood vessels. Studies in mice and small studies in humans have shown that statins also reduce the thickness of heart muscle, but this needed to be confirmed in a larger study.”

This study investigated the association between statins and heart structure and function. The study included 4,622 people without cardiovascular disease from the U.K. Biobank, a large community-based cohort study. Cardiac magnetic resonance imaging was used to measure left and right ventricular volumes and left ventricular mass. Information on statin use was obtained from medical records and a self-reporting questionnaire.

The relationship between statin use and heart structure and function was assessed using a statistical technique called multiple regression, which adjusts for potential confounders that can have an effect on the heart such as ethnicity, gender, age and body mass index (BMI).

Nearly 17 percent of participants were taking statins. Those taking statins were older, had higher BMI and blood pressure, and were more likely to have diabetes and hypertension. “This was not surprising because we prescribe statins to patients at high risk of heart disease and these are all known risk factors,” said Aung.

Patients taking statins had a 2.4 percent lower left ventricular mass and lower left and right ventricular volumes. Aung said: “People using statins were less likely to have a thickened heart muscle (left ventricular hypertrophy) and less likely to have a large heart chamber. Having a thick, large heart is a strong predictor of future heart attack, heart failure or stroke, and taking statins appears to reverse the negative changes in the heart which, in turn, could lower the risk of adverse outcomes.”

“It is important to note that in our study, the people taking statins were at higher risk of having heart problems than those not using statins yet they still had positive heart remodeling compared to the healthier control group,” added Aung.

In terms of how statins might reduce the thickness and volume of the heart, Aung said several studies have demonstrated that statins reduce oxidative stress and dampen the production of growth factors which stimulate cell growth. Statins also increase the production of nitric oxide by the cells lining the blood vessels, leading to vasodilatation, improved blood flow, lower blood pressure, and lower stress on the heart, which is less likely to become hypertrophied.

The findings raise the issue of extending statin prescriptions to anyone above the age of 40, but Aung said that was probably not the way to go.

“There are clear guidelines on who should receive statins,” he said. “There is debate about whether we should lower the bar and the question is when do you stop. What we found is that for patients already taking statins, there are beneficial effects beyond cholesterol lowering and that’s a good thing. But instead of a blanket prescription we need to identify people most likely to benefit — i.e. personalized medicine.”

Aung concluded: “A dual approach should be considered to identify people who will benefit most from statins. That means looking at not only clinical risk factors such as smoking and high blood pressure, but also genetic (hereditary) factors which can predict individuals’ response to statins. This is an area of growing interest and one that we are also investigating in our lab with our collaborators.”

For more information: www.escardio.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Overlay Init